Sperling Gabriel, Wang Yinghong
School of Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Case Rep Gastroenterol. 2022 Nov 8;16(3):618-622. doi: 10.1159/000526649. eCollection 2022 Sep-Dec.
We describe the unique case of a 73-year-old man who developed diffuse metastatic melanoma throughout the GI tract following potent immunosuppressive treatment for his immune-mediated colitis. Diagnosis of his metastatic GI luminal disease was confirmed with colonoscopy and EGD biopsies. Immunosuppressive therapy including corticosteroids and vedolizumab is the mainstay treatment for immune-mediated colitis and has generally been thought to have a safe toxicity profile. This unique case of diffuse luminal metastasis of melanoma after intensive immunosuppressant treatment raised the concern of their long-term safety on the cancer outcome and the need for safer alternatives.
我们描述了一例独特病例,一名73岁男性在接受针对免疫介导性结肠炎的强效免疫抑制治疗后,胃肠道出现弥漫性转移性黑色素瘤。通过结肠镜检查和上消化道内镜活检确诊了他的转移性胃肠道腔内疾病。包括皮质类固醇和维多珠单抗在内的免疫抑制疗法是免疫介导性结肠炎的主要治疗方法,一般认为其毒性特征较为安全。这例在强化免疫抑制治疗后出现黑色素瘤弥漫性腔内转移的独特病例引发了对其对癌症预后长期安全性的担忧,以及对更安全替代方案的需求。